Literature DB >> 9647281

The lesion in multiple sclerosis: clinical, pathological, and magnetic resonance imaging considerations.

H F McFarland1.   

Abstract

Despite the cause of multiple sclerosis remaining elusive, recent studies of the disease using magnetic resonance imaging (MRI) and detailed pathological analysis have provided new insights into the events involved in the evolution of the lesion in multiple sclerosis. Most evidence points to disruption of the blood-brain barrier as the initial event in development of the lesion in multiple sclerosis. It is thought that antigen specific T cells enter the nervous system, recognise antigen, and begin a cytokine cascade that mediates disruption of the blood-brain barrier seen on contrast enhanced MRI. Subsequently, the inflammatory response is amplified and the effector stage leading to myelin damage is initiated. The mechanism(s) causing myelin damage is uncertain. MRI and pathological studies now indicate that damage to the axon may occur earlier in lesion development than generally thought. Although T2 weighted MRI techniques lack pathological specificity, considerable attention is now focused on studying newer techniques that should provide greater insight into lesion development. These include studies of hypointensities on T1 weighted images, proton spectroscopy, magnetisation transfer imaging, and diffusion imaging. Hopefully, these new techniques will provide a better understanding of events involved in the multiple sclerosis lesion as well as an improved understanding of the relation between disease as measured on MRI and that seen clinically.

Entities:  

Mesh:

Year:  1998        PMID: 9647281

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

Review 1.  Nanomaterial applications in multiple sclerosis inflamed brain.

Authors:  Clara Ballerini; Giovanni Baldi; Alessandra Aldinucci; Pietro Maggi
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-24       Impact factor: 4.147

2.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.

Authors:  Fabrice Bonneville; David M Moriarty; Belinda S Y Li; James S Babb; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 3.  Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

Authors:  D J Rigotti; M Inglese; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-05       Impact factor: 3.825

4.  Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions.

Authors:  S Roychowdhury; J A Maldjian; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2000-05       Impact factor: 4.966

5.  Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.

Authors:  Ralf Gold; Gavin Giovannoni; J Theodore Phillips; Robert J Fox; Annie Zhang; Jing L Marantz
Journal:  Neurol Ther       Date:  2016-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.